Efficient Blockade of Akt signaling is a determinant factor to overcome resistance to Matuzumab

Abstract

BackgroundClinical studies have shown antineoplastic effectiveness of monoclonal antibodies (MAbs) against EGFR for different indications. Several MAbs directed to EGFR were developed recently, such as matuzumab, but there is still lack of information on preclinical data on its combination with chemo-radiation. Thus, the present study intended to examine the molecular pathways triggered by matuzumab alone or associated to chemo-radiotherapy in gynecological cell lines and its impact on cell growth and signaling.ResultsCombination of matuzumab with radiation and cisplatin did not enhance its cytostatic effects on A431, Caski and C33A cells (high, intermediate and low EGFR expression, respectively) in clonogenic assays, when compared to controls. The lack of effect was mediated by persistent signaling through EGFR due to its impaired degradation. In spite of the fact that matuzumab inhibited phosphorylation of EGFR, it had no effect upon cell viability. To analyze which downstream molecules would be involved in the EGFR signaling in the presence of matuzumab, we have tested it in combination with either PD98059 (MAPK inhibitor), or LY294002 (PI3K inhibitor). Matuzumab exhibited a synergic effect with LY294002, leading to a reduction of Akt phosphorylation that was followed by a decrease in A431 and Caski cells survival. The combination of PD98059 and matuzumab did not show the same effect suggesting that PI3K is an important effector of EGFR signaling in matuzumab-treated cells. Nonetheless, matuzumab induced ADCC in Caski cells, but not in the C33A cell line, suggesting that its potential therapeutic effects in vitro are indeed dependent on EGFR expression.ConclusionsMatuzumab combined with chemoradiation did not induce cytotoxic effects on gynecological cancer cell lines in vitro, most likely due to impaired EGFR degradation. However, a combination of matuzumab and PI3K inhibitor synergistically inhibited pAkt and cell survival, suggesting that the use of PI3K/Akt inhibitors could overcome intrinsic resistance to matuzumab in vitro. Altogether, data presented here can pave the way to a rational design of clinical strategies in patients with resistant profile to anti-EGFR inhibitors based on combination therapy.

Ataxin-1 is involved in tumorigenesis of cervical cancer cells via the EGFR-RAS–MAPK signaling pathway

“…To identify the molecular mechanism underlying cell growth in cervical cancer promoted by ATXN1, we analyzed the relevant regulatory signaling pathways. EGF induces cell growth in human cancer cells [ 19 ] and activates the Akt and ERK signaling pathways [ 31 , 32 ]. Considering this, we hypothesized that ATXN1 is involved in EGF-mediated cancer growth.…”

The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models

“…We selected human squamous cell cancer models with different sensitivities to the anti-EGFR mAb cetuximab, including A431 and FaDu cells, described as sensitive ( Tijink et al , 2006 ; Meira et al , 2011 ), and Detroit562 and Kyse30 cells, described as poorly sensitive to EGFR inhibitors ( Jimeno et al , 2007 ). According to the Sanger Institute catalogue of somatic mutations in cancer (*COSMIC database, Catalogue of Somatic Mutations In Cancer, http://www.sanger.ac.uk/ ), the mutational profile of the above cited cell lines is reported: Detroit562 cells harbour a H1047R mutation in the PI3K gene; Kyse30 cells harbour a Q61L mutation in the H-Ras gene.…”

Graphene nanoribbons elicit cell specific uptake and delivery via activation of epidermal growth factor receptor enhanced by human papillomavirus E5 protein

“…Six cell lines that showed increased LDH release (HeLa, CaSki, SiHa, MDA-MB-231, A431 and U251 cells) either over-express EGFR on their surface and/or have integrated HPV genome/genomes[18, 20–22, 28]. The other cell lines show low or normal EGFR expression [19, 23–26]. HeLa,CaSki and MDA-MB-231 cells, that either possess integarted HPV genome/s or overexpress EGFR or both, and do not express P-gp, exhibited the highest LDH release.…”